ACTG vs REGN · rev $285.2M vs P/E 14, rev $14.34B
Acacia Research Corporation (ACTG) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Acacia Research Corporation (ACTG) is a business equipment & supplies company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ACTG revenue for 2025-12-31 was $285.2M. Net income was $21.7M. Revenue was up 133.2% from 2024-12-31 to 2025-12-31. ACTG currently screens at market cap $452.0M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ACTG currently screens at market cap $452.0M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ACTG and REGN stock pages for the full models.
Not investment advice.